Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers
- 1 August 2011
- journal article
- Published by Elsevier BV in Cancer Cell
- Vol. 20 (2), 158-172
- https://doi.org/10.1016/j.ccr.2011.07.011
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverScience Translational Medicine, 2010
- A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid MalignanciesClinical Cancer Research, 2009
- The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor geneOncogene, 2009
- Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2009
- The ErbB kinase domain: Structural perspectives into kinase activation and inhibitionExperimental Cell Research, 2009
- Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary GlandsJournal of Clinical Oncology, 2007
- Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsNature Biotechnology, 2007
- ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surfaceFEBS Letters, 2004
- ErbB Receptors: Directing Key Signaling Networks Throughout LifeAnnual Review of Pharmacology and Toxicology, 2004
- The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB ReceptorsMolecular Cell, 2003